Pharmaceutical composition
AssigneeAstraZeneca AB
InventorsSvante Ross, Seth-Olov Thorberg
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition comprising of a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in the form of the free base, pharmaceutically acceptable salts and/or solvates thereof, and a second component (b) which is a monoamine oxidase (MAO) inhibitor in the form of the free base, pharmaceutically acceptable salts and/or solvates thereof, the preparation thereof, pharmaceutical formulations containing said composition, a kit containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition.
Claims19
A composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in the form of the free base, or a pharmaceutically acceptable salt or solvate thereof, and a second component (b) which is a monoamine oxidase inhibitor in the form of the free base, or a pharmaceutically acceptable salt or solvate thereof.
A kit containing a dosage unit of a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide in the form of the free base, or a pharmaceutically acceptable salt or solvate thereof;
- and (b) a dosage unit of a second unit of a second component which is a monoamine oxidase inhibitor in the form of a free base, or a pharmaceutically acceptable salt or solvate thereof, optionally with instructions for use.
Dependencies are inferred from the claim text.